Compare · BSX vs SONX
BSX vs SONX
Side-by-side comparison of Boston Scientific Corporation (BSX) and Sonendo Inc. (SONX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SONX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.39B, about 376.0x SONX ($192.5M).
- BSX has hit the wire 12 times in the past 4 weeks while SONX has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 6 for SONX).
- Company
- Boston Scientific Corporation
- Sonendo Inc.
- Price
- $48.71+0.31%
- $0.23-5.15%
- Market cap
- $72.39B
- $192.5M
- 1M return
- -13.91%
- -
- 1Y return
- -51.31%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 6
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Sonendo Inc.
Sonendo, Inc. develops, manufactures, and sells devices for root canal therapy in the United States and Canada. It offers GentleWave, a device to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. Sonendo, Inc. was incorporated in 2006 and is based in Laguna Hills, California.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest SONX
- Amendment: SEC Form SCHEDULE 13G/A filed by Sonendo Inc.
- Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
- Sonendo, Inc. Reports Second Quarter 2025 Financial Results and Reaffirms Financial Guidance
- Sonendo, Inc. Reports First Quarter 2025 Financial Results and Issues Financial Guidance
- SEC Form D filed by Sonendo Inc.
- Sonendo, Inc. Announces $5.0 Million Private Placement
- SEC Form 10-K filed by Sonendo Inc.
- Sonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
- SEC Form EFFECT filed by Sonendo Inc.
- SEC Form EFFECT filed by Sonendo Inc.